Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 229,111 shares of the biopharmaceutical company's stock after purchasing an additional 10,729 shares during the period. Vontobel Holding Ltd.'s holdings in Gilead Sciences were worth $25,672,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GILD. FMR LLC grew its position in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp grew its position in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares in the company, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock worth $6,340,745 in the last 90 days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $0.24 during trading on Friday, hitting $111.28. 4,039,811 shares of the stock were exchanged, compared to its average volume of 7,706,267. The stock's fifty day moving average is $107.02 and its 200 day moving average is $104.02. The stock has a market cap of $138.42 billion, a PE ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 12 month low of $66.34 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.32) EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.